Published in

Nature Research, npj Vaccines, 1(7), 2022

DOI: 10.1038/s41541-022-00455-3

Links

Tools

Export citation

Search in Google Scholar

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

Journal article published in 2021 by Michael Karbiener ORCID, Maria R. Farcet, Andreas Zollner ORCID, Taisei Masuda, Mitsuhiro Mori, Alexander R. Moschen ORCID, Thomas R. Kreil ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractSARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and a vector-based (Vaxzevria) COVID-19 vaccine, calibrated against the WHO international SARS-CoV-2 antibody standard, and further supports the use of neutralizing antibody levels as a correlate of protection.